Globus Medical (GMED) Expected to Post Earnings on Thursday

Globus Medical (NYSE:GMED) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Globus Medical to announce earnings of $1.20 per share and revenue of $792.39 million for the quarter. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The business had revenue of $789.61 million for the quarter, compared to analyst estimates of $782.88 million. During the same quarter in the previous year, the company posted $0.86 earnings per share. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. On average, analysts expect Globus Medical to post $4.99 EPS for the current fiscal year and $5.40 EPS for the next fiscal year.

Globus Medical Price Performance

Shares of NYSE GMED opened at $79.53 on Tuesday. The stock has a fifty day moving average price of $77.49 and a 200 day moving average price of $83.45. Globus Medical has a 1-year low of $59.51 and a 1-year high of $101.40. The company has a market cap of $10.68 billion, a PE ratio of 20.34, a P/E/G ratio of 1.31 and a beta of 0.96.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. UBS Group started coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price objective for the company. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a report on Friday, October 9th. BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a research note on Friday, September 18th. Stifel Nicolaus dropped their price target on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a research note on Wednesday, July 8th. Finally, Zacks Research raised shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Globus Medical presently has a consensus rating of “Moderate Buy” and an average target price of $99.46.

Insider Buying and Selling

In other Globus Medical news, Director James Tobin sold 30,000 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the completion of the transaction, the director owned 15,000 shares in the company, valued at approximately $1,118,700. This represents a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Stephen T. Zarrilli sold 25,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the transaction, the director owned 25,000 shares of the company’s stock, valued at $2,176,000. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. 18.38% of the stock is owned by insiders.

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.